Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
Hisert KB, Birket SE, Clancy JP, Downey DG, Engelhardt JF, Fajac I, Gray RD, Lachowicz-Scroggins ME, Mayer-Hamblett N, Thibodeau P, Tuggle KL, Wainwright CE, De Boeck K. Hisert KB, et al. Among authors: gray rd. Lancet Respir Med. 2023 Oct;11(10):916-931. doi: 10.1016/S2213-2600(23)00324-7. Epub 2023 Sep 9. Lancet Respir Med. 2023. PMID: 37699420 Review.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Middleton PG, et al. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. N Engl J Med. 2019. PMID: 31697873 Free PMC article. Clinical Trial.
Biomarkers to monitor exacerbations in cystic fibrosis.
Gray RD, Downey D, Taggart CC. Gray RD, et al. Expert Rev Respir Med. 2017 Apr;11(4):255-257. doi: 10.1080/17476348.2017.1307739. Expert Rev Respir Med. 2017. PMID: 28299964 No abstract available.
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.
Meijer L, Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. Meijer L, et al. Among authors: gray rd. J Innate Immun. 2016;8(4):330-49. doi: 10.1159/000444256. Epub 2016 Mar 18. J Innate Immun. 2016. PMID: 26987072 Free PMC article. Review.
Itaconate controls the severity of pulmonary fibrosis.
Ogger PP, Albers GJ, Hewitt RJ, O'Sullivan BJ, Powell JE, Calamita E, Ghai P, Walker SA, McErlean P, Saunders P, Kingston S, Molyneaux PL, Halket JM, Gray R, Chambers DC, Maher TM, Lloyd CM, Byrne AJ. Ogger PP, et al. Sci Immunol. 2020 Oct 23;5(52):eabc1884. doi: 10.1126/sciimmunol.abc1884. Sci Immunol. 2020. PMID: 33097591 Free PMC article.
Climate, climate change and the global diversity of human houses.
Dunn RR, Kirby KR, Bowern C, Ember CR, Gray RD, McCarter J, Kavanagh PH, Trautwein M, Nichols LM, Gavin MC, Botero C. Dunn RR, et al. Among authors: gray rd. Evol Hum Sci. 2024 Mar 20;6:e24. doi: 10.1017/ehs.2024.5. eCollection 2024. Evol Hum Sci. 2024. PMID: 38689895 Free PMC article.
251 results